Molecular analysis of the IL-2 receptor beta chain gene expressed in human tumor cells.
Interleukin-2 (IL-2) is recognized as a T cell growth factor. We have previously reported that human carcinoma cell lines are inhibited in growth by exogenous IL-2, which binds to the IL-2 receptor beta (IL-2Rbeta) chain ubiquitously expressed on the surface of tumor cells. A possibility was considered that IL-2Rbeta on carcinomas responsible for negative signaling was different from that expressed on hematopoietic cells. To investigate this possibility, mRNA for the IL-2Rbeta chain was amplified and compared in carcinoma and lymphoid cells. Using RT-PCR with pairs of sense-antisense oligonucleotide primers specific for the various regions of extracellular, transmembrane and intracellular domains of the IL-2Rbeta chain, we amplified mRNA obtained from three human carcinoma cell lines and human lymphoid cells as controls. The identity of the amplicons was confirmed by Southern analysis with the 32P-labeled cDNA probe coding for the entire span of the IL-2Rbeta chain. In addition, genomic DNA obtained from the tumor cell lines was sequenced to examine the possibility that a mutation is present in the gene coding for the intracellular IL-2Rbeta chain domain. No mutations or deletions were detected. The message for all three domains of the beta chain was identical in tumor cells and in normal lymphoid cells used as controls. Also, by Western blot and northern analyses no differences between IL-2Rbeta chain in tumors vs that expressed in lymphoid cells were demonstrable. The IL-2Rgamma chain, which participates in IL-2/IL-2R signaling pathway, was expressed in tumor cells. Expression of JAK1 transcripts in these cells was comparable to that in lymphocytes. However, RT-PCR analysis identified differences in expression of JAK3 splice variants (B and M) in tumor cells. These differences may be responsible for altered downstream signaling by IL-2. Overall, our data indicate that the same IL-2/IL-2R pathway is operative in human carcinomas and in normal epithelial or lymphoid cells.
Suminami
Y
Y
The University of Pittsburgh Cancer Institute and Department of Pathology, University of Pittsburgh School of Medicine, Pennsylvania 15213, USA.
Kashii
Y
Y
Law
J C
JC
Lin
W C
WC
Stanson
J
J
Reichert
T E
TE
Rabinowich
H
H
Whiteside
T L
TL
D002292:Carcinoma, Renal Cell; D017931:DNA Primers; D006258:Head and Neck Neoplasms; D006801:Humans; D053613:Janus Kinase 1; D019169:Jurkat Cells; D007680:Kidney Neoplasms; D008214:Lymphocytes / Q000201:enzymology / Q000276:immunology; D046911:Macromolecular Substances; D009369:Neoplasms / Q000235:genetics / Q000276:immunology*; D016376:Oligonucleotides, Antisense; D016133:Polymerase Chain Reaction; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis; D012333:RNA, Messenger / Q000096:biosynthesis; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis* / Q000737:chemistry / Q000235:genetics*; D013274:Stomach Neoplasms; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured
D017931:DNA Primers; D046911:Macromolecular Substances; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D015375:Receptors, Interleukin-2; D011505:Protein-Tyrosine Kinases; C507904:JAK1 protein, human; D053613:Janus Kinase 1